CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Short Interest Update

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) was the recipient of a large increase in short interest in the month of August. As of August 31st, there was short interest totaling 63,600 shares, an increase of 65.2% from the August 15th total of 38,500 shares. Based on an average trading volume of 40,500 shares, the short-interest ratio is presently 1.6 days. Currently, 11.1% of the shares of the company are short sold. Currently, 11.1% of the shares of the company are short sold. Based on an average trading volume of 40,500 shares, the short-interest ratio is presently 1.6 days.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CNSP. Maxim Group upgraded CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $20.00 price target for the company in a research report on Friday, September 12th. Alliance Global Partners restated a “buy” rating on shares of CNS Pharmaceuticals in a research note on Thursday, May 22nd. Finally, Wall Street Zen downgraded shares of CNS Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 5th. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $20.00.

Institutional Trading of CNS Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC increased its holdings in CNS Pharmaceuticals by 1,712.3% in the 4th quarter. Jane Street Group LLC now owns 419,737 shares of the company’s stock worth $51,000 after acquiring an additional 396,577 shares in the last quarter. Armistice Capital LLC purchased a new stake in CNS Pharmaceuticals in the second quarter valued at $335,000. Citadel Advisors LLC purchased a new position in CNS Pharmaceuticals during the fourth quarter worth about $39,000. Finally, Connective Capital Management LLC acquired a new stake in CNS Pharmaceuticals in the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

CNS Pharmaceuticals Stock Performance

CNSP opened at $9.14 on Wednesday. The stock has a market cap of $5.21 million, a price-to-earnings ratio of 0.00 and a beta of 2.61. CNS Pharmaceuticals has a one year low of $4.93 and a one year high of $221.94. The stock’s 50 day moving average price is $7.63 and its 200-day moving average price is $13.40.

CNS Pharmaceuticals (NASDAQ:CNSP) last posted its earnings results on Thursday, August 14th. The company reported ($6.42) EPS for the quarter, beating analysts’ consensus estimates of ($9.60) by $3.18.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.